Diagnosis and management of IBS in adults

American Family Physician

Volumn 86, Issue 5, 2012, Pages 419-426

  Wilkins Prof , Thad ^a   Pepitone, Christa ^a   Alex, Biju ^a   Schade, Robert R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DICYCLOVERINE; DOXEPIN; FLUOXETINE; HYOSCYAMINE; IMIPRAMINE; ISPAGULA; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MACROGOL 3350; NEOMYCIN; PAROXETINE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALTERNATIVE MEDICINE; ARTICLE; BLURRED VISION; CLINICAL FEATURE; CONSTIPATION; DEATH; DEFECATION; DIARRHEA; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; FECES; FIBER; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; KINESIOTHERAPY; MUCUS; NAUSEA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; XEROSTOMIA;

EID: 84866445260     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al.; American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.
2. Locke GR III. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am. 1996;25(1):1-19.
3. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122(2):107-112.
4. Saito YA, Petersen GM, Larson JJ, et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol. 2010;105(4):833-841.
5. Camilleri M. Evolving concepts of the pathogenesis of irritable bowel syndrome: to treat the brain or the gut? J Pediatr Gastroenterol Nutr. 2009;48(suppl 2):S46-S48.
6. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(4):349-357.
7. White DL, Savas LS, Daci K, et al. Trauma history and risk of the irritable bowel syndrome in women veterans. Aliment Pharmacol Ther. 2010;32(4):551-561.
8. Spiller R, Aziz Q, Creed F, et al.; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management [published correction appears in Gut. 2008;57(12):1743]. Gut. 2007;56(12):1770-1798.
9. Creed F, Guthrie E, Ratcliffe J, et al. Reported sexual abuse predicts impaired functioning but a good response to psychological treatments in patients with severe irritable bowel syndrome. Psychosom Med. 2005;67(3):490-499.
10. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535-544.
11. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders [published correction appears in Gastroenterology. 2006;131(2):688]. Gastroenterology. 2006;130(5):1480-1491.
12. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? [published correction appears in JAMA. 2009;301(15):1544]. JAMA. 2008;300(15):1793-1805.
13. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920-924.
14. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27(1):37-40.
15. Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol. 2005;19(4):231-234.
16. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402.
17. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169(7):651-658.
18. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-922.
19. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodic and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011(8):CD003460.
20. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(1):191-196.
21. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(11-12):1253-1269.
22. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
23. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
24. Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
25. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51(8):1297-1301.
26. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
27. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis [published correction appears in BMJ. 2009;338:b1881]. BMJ. 2008;337:a2313.
28. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367-378.
29. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009(1):CD006442.
30. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007(4):CD005110.
31. Lim B, Manheimer E, Lao L, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006(4):CD005111.
32. Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome Cochrane Database Syst Rev. 2006(1):CD004116.
33. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104(7):1831-1843.
34. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev. 2007(4):CD003960.